JP2020536096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536096A5 JP2020536096A5 JP2020519131A JP2020519131A JP2020536096A5 JP 2020536096 A5 JP2020536096 A5 JP 2020536096A5 JP 2020519131 A JP2020519131 A JP 2020519131A JP 2020519131 A JP2020519131 A JP 2020519131A JP 2020536096 A5 JP2020536096 A5 JP 2020536096A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer cells
- amino acids
- composition according
- free amino
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 15
- 235000001014 amino acid Nutrition 0.000 claims 11
- 229940024606 amino acid Drugs 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 235000004554 glutamine Nutrition 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 235000014705 isoleucine Nutrition 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023144987A JP2023171755A (ja) | 2017-10-02 | 2023-09-07 | 腫瘍成長を阻害するための材料および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566787P | 2017-10-02 | 2017-10-02 | |
| US62/566,787 | 2017-10-02 | ||
| PCT/US2018/054015 WO2019070750A1 (en) | 2017-10-02 | 2018-10-02 | MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023144987A Division JP2023171755A (ja) | 2017-10-02 | 2023-09-07 | 腫瘍成長を阻害するための材料および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536096A JP2020536096A (ja) | 2020-12-10 |
| JP2020536096A5 true JP2020536096A5 (https=) | 2021-11-11 |
| JP7352901B2 JP7352901B2 (ja) | 2023-09-29 |
Family
ID=64049688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519131A Active JP7352901B2 (ja) | 2017-10-02 | 2018-10-02 | 腫瘍成長を阻害するための材料および方法 |
| JP2023144987A Pending JP2023171755A (ja) | 2017-10-02 | 2023-09-07 | 腫瘍成長を阻害するための材料および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023144987A Pending JP2023171755A (ja) | 2017-10-02 | 2023-09-07 | 腫瘍成長を阻害するための材料および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12109191B2 (https=) |
| EP (1) | EP3691628A1 (https=) |
| JP (2) | JP7352901B2 (https=) |
| KR (1) | KR102709096B1 (https=) |
| CN (2) | CN111417391B (https=) |
| CA (1) | CA3078335A1 (https=) |
| WO (1) | WO2019070750A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| WO2019224428A1 (en) * | 2018-05-22 | 2019-11-28 | Seleq Oy | Pharmaceutical compositions for the treatment of cancer |
| IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
| IT201900002109A1 (it) | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
| IT202000000454A1 (it) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro |
| IT202000000442A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
| CA3177780A1 (en) * | 2020-05-29 | 2021-12-02 | University Of Florida Research Foundation, Inc. | Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis |
| CN115192564B (zh) * | 2022-05-23 | 2023-11-17 | 四川大学华西医院 | 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用 |
| US11878073B1 (en) | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPH01301619A (ja) * | 1988-05-30 | 1989-12-05 | Otsuka Pharmaceut Factory Inc | 癌用アミノ酸製剤 |
| JPH0368514A (ja) | 1989-08-09 | 1991-03-25 | Morishita Pharmaceut Co Ltd | 癌用アミノ酸製剤 |
| WO1993006934A1 (en) | 1991-09-30 | 1993-04-15 | Devtech Labs, Inc. | Electrostatic separation of plastic materials |
| US5658895A (en) | 1991-10-07 | 1997-08-19 | Otsuka Pharmaceutical Factory, Inc. | Anticancer enteral feeding composition |
| DE69229910T2 (de) | 1991-10-07 | 2000-04-20 | Otsuka Pharmaceutical Factory, Inc. | Enterale zubereitungen zur krebstherapie |
| JP3429327B2 (ja) | 1992-07-20 | 2003-07-22 | 味の素ファルマ株式会社 | 癌用アミノ酸輸液剤 |
| JPH06256184A (ja) | 1993-03-05 | 1994-09-13 | Morishita Roussel Kk | 癌患者用アミノ酸製剤 |
| JP4683881B2 (ja) | 2003-08-27 | 2011-05-18 | 有限会社アーク技研 | 抗腫瘍活性剤 |
| US20050176807A1 (en) * | 2004-02-09 | 2005-08-11 | Friesen Kim G. | Composition and method for use in cartilage affecting conditions |
| US20060052454A1 (en) * | 2004-08-09 | 2006-03-09 | Enrique Melendez Hevia | Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders |
| MX350541B (es) | 2010-09-24 | 2017-09-08 | Univ Florida | Materiales y metodos para mejorar la funcion gastrointestinal. |
| WO2015003021A2 (en) | 2013-07-01 | 2015-01-08 | The Trustees Of Princeton University | Dietary supplements and composition for treating cancer |
| EP3352586A4 (en) * | 2015-09-21 | 2019-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | NUTRITIONAL TREATMENT FOR CANCER DISEASES |
-
2018
- 2018-10-02 EP EP18795844.2A patent/EP3691628A1/en active Pending
- 2018-10-02 CN CN201880076756.0A patent/CN111417391B/zh active Active
- 2018-10-02 WO PCT/US2018/054015 patent/WO2019070750A1/en not_active Ceased
- 2018-10-02 CN CN202410201525.5A patent/CN118078810A/zh active Pending
- 2018-10-02 JP JP2020519131A patent/JP7352901B2/ja active Active
- 2018-10-02 KR KR1020207012608A patent/KR102709096B1/ko active Active
- 2018-10-02 CA CA3078335A patent/CA3078335A1/en active Pending
- 2018-10-02 US US16/652,973 patent/US12109191B2/en active Active
-
2023
- 2023-09-07 JP JP2023144987A patent/JP2023171755A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536096A5 (https=) | ||
| MX2020013373A (es) | Compuestos de naftiridinona utiles como activadores de celulas t. | |
| ES2880103T3 (es) | Derivados de benceno-1, 3, 5-tricarboxamida y usos de los mismos | |
| JP2026041749A5 (https=) | ||
| IL308807B2 (en) | Combination therapy for treating cancer | |
| JP2021502980A5 (https=) | ||
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| EP2308885A3 (en) | Novel compounds and methods for therapy | |
| RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
| JP2007515393A5 (https=) | ||
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| JP2014506913A5 (https=) | ||
| EP3276004A3 (en) | Methods for treating chronic kidney disease | |
| JP2008535902A5 (https=) | ||
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2013503110A5 (https=) | ||
| RU2015149010A (ru) | Биологические маркеры, которые могут быть использованы в иммунотерапии рака | |
| JP2017513908A5 (https=) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2013172743A5 (https=) | ||
| JP2018505223A5 (https=) | ||
| JP2019501206A5 (https=) | ||
| JP2010536714A5 (https=) | ||
| JP2015512943A5 (https=) |